Iambic Raises Over $100 Million in an Oversubscribed Round to Advance its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies

Iambic to Participate in November Investor Conferences

Promise & Reality: Decoding AI’s Impact On Drug Development

From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery

Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer

Iambic Shares Clinical Data from Ph1/1B Study of IAM1363, a Highly Selective Type-2 HER2 Inhibitor, Demonstrating Monotherapy Activity in Heavily Pretreated Patients with HER2 Alterations, at the 2025 ESMO Congress

A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations

Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors

Enchant: A Multi-Modal Transformer Model to Break Down the Data Wall between Preclinical and Clinical Research and Development